Newspaper publication for Un-audited Financial Results for the quarter and half year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech has submitted copies of newspaper advertisements published on November 16, 2025 in 'Financial Express' (English) and 'Nava Telangana' (Telugu), as required under SEBI Listing Regulations. The advertisements contain the un-audited consolidated and standalone financial results for Q2 FY26 and H1 FY26 (period ended September 30, 2025). On a consolidated basis, Q2 FY26 revenue from operations stood at Rs. 1,324.29 lacs (vs Rs. 1,666.61 lacs in Q2 FY25), with profit after tax at Rs. 86.86 lacs (vs Rs. 523.36 lacs in Q2 FY25). For H1 FY26, total income was Rs. 2,589.23 lacs and profit after tax was Rs. 220.57 lacs, compared with Rs. 2,681.26 lacs and Rs. 540 lacs respectively in H1 FY25. Basic EPS for Q2 FY26 was Rs. 0.46 (vs Rs. 3.51 in Q2 FY25) and for H1 FY26 was Rs. 3.62 (vs Rs. 4.76 in H1 FY25). Results were approved by the Board on November 14, 2025.
The filing itself is a routine regulatory compliance disclosure, not new news. However, the published numbers reveal a sharp year-on-year decline in both revenue (~21% lower in Q2) and profit after tax (~83% lower in Q2), which is a negative signal for shareholders. Investors should watch the full results for reasons behind the steep profit drop, but no direct stock price catalyst is expected from this newspaper publication alone.